Drug Database
Back to search

Poland· PL-100481577

Calquence

A acalabrutinib product containing acalabrutinibum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 14 of our 19 countries.

ATC L01EL02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCalquenceATCL01EL02REGISTER NO.PL-100481577PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about acalabrutinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Acalabrutinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EL02 (acalabrutinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search acalabrutinib products by name

Acalabrutinib · ATC L01EL02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of acalabrutinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $190.74 in Switzerland — a ×1172 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Acalabrutinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$190.74
  • FR France$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Acalabrutinibum
Manufacturer
AstraZeneca AB
Country
Poland (PL)
ATC code
L01EL02
ATC class
Acalabrutinib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05000456071116

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

375 interactions on record for acalabrutinib.

Graded by severity as the source publishes them — 201 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check acalabrutinib against other medicinesHow interaction checks work

Acalabrutinib · interactions on record

375 records

  • 201 severe
  • 174 moderate

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Acalabrutinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All acalabrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Calquence
  • Liechtenstein · Calquence
  • Norway · Calquence

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3f15a0e4-2542-41d1-aa9e-b3fb0705d2ff
GET /v1/drugs/3f15a0e4-2542-41d1-aa9e-b3fb0705d2ff?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "Rpz ¦ EU/1/20/1479/003 ¦ 149592\n56 tabl.\n05000456071116 ¦ Rpz ¦ EU/1/20/1479/004 ¦ 149593\n60 tabl.",
  "substance": "Acalabrutinibum 100 mg",
  "common_name": "Acalabrutinibum",
  "pl_product_id": "100481577",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about acalabrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console